News

Imbalance between IOP and cerebrospinal fluid pressure may influence the risk of normal-tension glaucoma or the susceptibility of the optic nerve to ocular hypertension.

n this installment of Sight Lines, J.C. Noreika, MD, MBA, talks with Michael L. Stark, JD, who has represented physicians for more than 50 years as his primary client base. Among the topics they discuss is the watershed moment that enabled physicians to incorporate and take advantage of business-tax deduction provisions.

Low perfusion pressure is a risk factor for glaucoma, however, the understanding of the role of perfusion pressure in the disease must be clarified.

Cornea experts discuss the roles of ocular surface transplantation and keratoprosthesis implantation in the management of eyes with severe limbal stem cell deficiency.

Beyond the official handbook, employees will also come with their own “rules of survival” that they expect the clinic to follow. Unfortunately, the practice will have no idea what the rules-or deviation of the rules-are until they occur.

Microstent implantation had favorable and safe results in a group of patients with open-angle glaucoma in the DUETTE trial.

Eyes undergoing implantation with an investigational Schlemm’s canal microstent at the time of cataract surgery achieve significantly greater IOP control than eyes having cataract surgery alone.

Switching from brand to generic eye drops for surgical prophylaxis following cataract surgery caused no difference in endophthalmitis rates and resulted in substantial cost savings in a single-center comparison.

: Highlights are presented from what is believed to be the first head-to-head comparison of one, two, and three stents inserted as a stand-alone procedure.

Capturing clinical images with the integration of electronic health records and smartphone applications can enhance practice efficiency and compliance.

The initial 36-month results are highlighted from a novel, soft and permanent, minimally invasive ab interno collagen implant used to optimize aqueous drainage to the subconjunctival space.

A potent and selective transforming growth factor (TGF)-β2 LNA-modified antisense oligonucleotide induces biologic responses consistent with the drug’s expected molecular mechanism of action in different preclinical ocular surface disease models.

A proprietary glaucoma device has changed current thinking about cyclophotocoagulation by offering another option in the glaucoma treatment algorithm and allowing earlier laser intervention when medical treatment comes up short.

Following specific steps in the retail-selling process will increase the likelihood that customers will make a purchase.

Active research in neuroprotection, neuroregeneration, and sustained drug delivery is expected to lead to better options for management of glaucoma.

Endoscopic cyclophotocoagulation with vitrectomy and pars plana treatment is effective in reducing IOP in patients with ultra-refractory glaucoma, reducing the need for medications and being relatively well tolerated by patients.

In this physician perspective, Robert J. Noecker, MD, MBA, describes the results he has experienced since he has begun applying an ocular sealant as the last step of every filtering procedure.

What would happen if all ophthalmic staff were allocated such a salary?

There has been growing concern within the medical industry that senior physicians can negatively impact patient care.

A new gene therapy could preserve vision in people with retinitis pigmentosa and might effectively treat other degenerative nerve disorders.

Experts break down the most prevalent falsities ophthalmologists believe about dispensaries, and why believing them are seriously hurting practice revenue.

In her latest blog, Donna Suter gives her advice on creating better communication with your patients.

Guidelines for Case Study Submissions

In her latest blog, Joy Gibb, ABOC, writes how ophthalmologists can fight UPP at the source-your patients.

Patients who are blind from retinitis pigmentosa continue to benefit from a safe retinal implant after 3 years, Ophthalmology reported

In his latest blog, Mark Packer, MD, reflects on ophthalmic pioneers of the past, and writes why controversy and challenging the norm is what drives the future of advancements.

It can be a daunting thought, but due to the ever-growing reliance of the web, do you really know what your patients think of your practice?

Santen recently launched fixed-combination tafluprost and timolol (TAPTIQOM) in the United Kingdom.